Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Current Assets for 7 consecutive years, with $72.7 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 33.87% year-over-year to $72.7 million; the TTM value through Mar 2026 reached $72.7 million, down 33.87%, while the annual FY2025 figure was $77.8 million, 38.14% down from the prior year.
  • Current Assets hit $72.7 million in Q1 2026 for Barinthus Biotherapeutics, down from $77.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $230.8 million in Q1 2022 and bottomed at $72.7 million in Q1 2026.
  • Average Current Assets over 5 years is $152.1 million, with a median of $143.1 million recorded in 2024.
  • Year-over-year, Current Assets soared 41.27% in 2022 and then plummeted 38.14% in 2025.
  • Barinthus Biotherapeutics' Current Assets stood at $213.0 million in 2022, then dropped by 26.35% to $156.9 million in 2023, then decreased by 19.86% to $125.7 million in 2024, then crashed by 38.14% to $77.8 million in 2025, then fell by 6.59% to $72.7 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $72.7 million, $77.8 million, and $86.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.